NCT04349371 is a Phase 2 clinical trial of Chloroquine in COVID, sponsored by Columbia University.

Who is sponsoring NCT04349371?

NCT04349371 is sponsored by Columbia University.

What drugs are being tested in NCT04349371?

Interventions in NCT04349371: Chloroquine, Placebo oral tablet.

What condition does NCT04349371 study?

NCT04349371 studies COVID, Coronavirus Infection.

Is NCT04349371 still recruiting?

NCT04349371 is currently terminated. Last updated 27 February 2025.

Are results published for NCT04349371?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-02-27 · How we verify

NCT04349371

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID

Terminated Phase 2 Results posted Last updated 27 February 2025

What this trial tests

Phase 2 trial testing Chloroquine in COVID in 5 participants. Terminated before completion.

Timeline

21 April 2020

Primary endpoint
11 February 2021

11 February 2021

Quick facts

Lead sponsor	Columbia University
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	5
Start date	21 April 2020
Primary completion	11 February 2021
Estimated completion	11 February 2021
Sites	1 location across United States

Drugs / interventions tested

Chloroquine (CHLOROQUINE) — full drug profile →
Placebo oral tablet — full drug profile →

Conditions studied

COVID — all drugs for COVID →
Coronavirus Infection — all drugs for Coronavirus Infection →

Sponsor

Columbia University

Who can join

18 and older, any sex, with COVID or Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective is to determine the clinical efficacy of Chloroquine (CQ) in health care workers with moderate to high risk of exposure to COVID-19 in preventing symptomatic COVID-19 infections. Secondary endpoints will explore the efficacy of CQ in preventing any infection as defined by seroconversion to positive anti-COVID antibody status.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, et al · · 2020 · cited 246× · PMID 32687918 · DOI 10.1016/j.lfs.2020.118102
Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation.
Gendrot M, Andreani J, Boxberger M, Jardot P, et al · · 2020 · cited 69× · PMID 32916297 · DOI 10.1016/j.tmaid.2020.101873
An up-to-date overview of computational polypharmacology in modern drug discovery.
Chaudhari R, Fong LW, Tan Z, Huang B, et al · · 2020 · cited 46× · PMID 32452701 · DOI 10.1080/17460441.2020.1767063
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
Slimano F, Baudouin A, Zerbit J, Toulemonde-Deldicque A, et al · · 2020 · cited 29× · PMID 32623296 · DOI 10.1016/j.ctrv.2020.102063
SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries.
Elshabrawy HA. · · 2020 · cited 28× · PMID 32585913 · DOI 10.3390/vaccines8020335
Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape.
Hossain MS, Hami I, Sawrav MSS, Rabbi MF, et al · · 2020 · cited 16× · PMID 33403227 · DOI 10.15190/d.2020.18
A perspective on potential target proteins of COVID-19: Comparison with SARS-CoV for designing new small molecules.
Kumar D, Chauhan G, Kalra S, Kumar B, et al · · 2020 · cited 16× · PMID 33142431 · DOI 10.1016/j.bioorg.2020.104326
Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic.
Bhandari R, Khanna G, Kuhad A. · · 2021 · cited 13× · PMID 33065092 · DOI 10.1016/j.ejphar.2020.173643

Verify or expand the search:

Other trials of Chloroquine

Trials testing the same drug.

NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT06666491 — An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken · Phase 3 · recruiting
NCT04704999 — Southeast Asia Dose Optimization of Tafenoquine · Phase 4 · recruiting
NCT02432417 — The Addition of Chloroquine to Chemoradiation for Glioblastoma, · Phase 2 · withdrawn
NCT05980156 — Comparing Chemoprevention Drugs for School-based Malaria Control · Phase 4 · completed

Other recruiting trials for COVID

Currently open trials in the same condition.

NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting

Other Columbia University trials

Trials by the same sponsor.

NCT06558422 — Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · not yet recruiting
NCT07264582 — HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking · NA · not yet recruiting
NCT05992415 — Know Your Pressures NYC · NA · not yet recruiting
NCT05645211 — The AgRP and GH/IGF-1 Axis in Children · not yet recruiting
NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04349371 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Columbia University
Last refreshed: 27 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04349371.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing